Introduction
Vitamin D3 (D3)' is a secosteroid produced in the skin from 7-dehydrocholesterol (1) . Once in circulation, D3 is taken up by the liver and hydroxylated at C-25 by a cytochrome P-450-dependent mixed function oxidase system. Two independent enzyme systems have been described in the microsomal (2) and mitochondrial (3) fractions, respectively. In view of its lower Km value (4), the microsomal D3-25 hydroxylase is considered as being physiologically more significant in the rat than the mitochondrial enzyme. The hepatic metabolite, however, 25-hydroxyvitamin D3 [25(0H)D3], has only weak biological activity and requires further hydroxylation at the C-la position before achieving its full hormonal potential. This reaction is catalyzed by a renal mitochondrial cytochrome P-450-dependent mixed function oxidase system, which is tightly regulated by stimulatory factors (hypocalcemia, parathyroid and growth hormones) associated with states of calcium demand as well as by the inhibitory regulation of hypercalcemia and 1,25-dihydroxyvitamin D3 (1 ,25(0H)2D3) itself (5, 6) . However, unlike that of the renal 25(OH)D3-la-hydroxylase, the regulation of the hepatic D3-25 hydroxylase is still rather ill defined. Early work by Bhattacharyya and De Luca (7) demonstrated that previous dosing with D3 diminished the liver's subsequent capacity to hydroxylate tritiated substrate. Later experiments by Rojanasathit and Haddad (8) , however, showed that the apparent in vivo hepatic limitations in 25(OH)D3 production could be overcome by increased substrate concentrations. Other groups (9-1 1) were also unable to confirm the importance of the vitamin D status in the control ofthe D3-25 hydroxylase activity in the liver. On the other hand, two recent reports have reopened the question of the regulation of the D3-25 hydroxylase. Indeed, following in vitro experiments in rat liver preparations (12) as well as following oral administration in humans (13) , the possibility has been raised that 1,25(OH)2D3 may be an inhibitor of the hepatic D3-25 hydroxylase activity.
The aim of the present studies was therefore to examine the differential effects of the hormone 1,25(OH)2D3 and of its associated physiological influence on the extracellular calcium concentration on the in vivo and in vitro metabolism of D3 to 25(OH)D3 in vitamin D-depleted rats.
Methods

Animals and treatment procedures
Nurturing female Sprague-Dawley rats with 14-d-old litters (Charles River, Ltd., St. Constant, Quebec, Canada) were housed in plastic wiretopped cages and fed ad lib. a vitamin D-deficient diet (14) containing 0.2 and 0. 18%, respectively, ofelementary calcium and phosphorus. Upon weaning, male rats were housed in hanging stainless steel wire cages and fed ad lib. the vitamin D-deficient diet as well as demineralized water for a period of 5-7 wk 
Serum parameters ofvitamin D depletion and of supplementation regimens
Serum vitamin D metabolites were measured after extraction and chromatogrsaphy as described earlier (15) . 25(OH)D was analyzed by a competitive protein binding assay using sheep serum in a dilution of 1:40,000 as binding protein; the lower limit of sensitivity of the method was 10 pg. ml1'. 1,25(OH)2D3 was measured by a competitive protein binding assay using a cytosolic receptor from bovine thymus ( 16); the lower limit ofsensitivity ofthe method was I pg* ml-'. Plasma calcium was measured by the colorimetric method ofGindler and King (17) . In order to evaluate the effect ofthe high 1,25(OH)2D3 dose on the renal function, the plasma creatinine and blood, urea nitrogen (BUN) concentrations were determined in controls and in the 65-pmol * 24 h-' group by standard methods adapted for multianalyzer analysis.
In vivo metabolism of['4C]D3 liver homogenates. Samples of liver homogenate (5 ml) were extracted using the procedure described above for the plasma samples with the following modifications: 20 ml ofthe extraction solvent system was used while no internal standards, ammonium carbonate, or distilled water were added. The combined organic phases were evaporated under a stream ofnitrogen. The liver extracts were dissolved in hexane and applied to silicic acid (Bio-Sil HA, Bio-Rad Laboratories, Richmond, CA) columns (0.6 X 5 cm in pasteur pipettes) and eluted with an isocratic gradient of hexane/ether (20, 40, 60 , and 100% ether, vol/vol) followed by a final methanol wash. Fractions of 1 ml were collected and counted in 5 ml of Ready-Solv HP/b (Beckman Instruments, Inc., Galway, Ireland) using two channels appropriate for "4C and 3H detection. All calculations were made after data reduction from counts per minute to disintegrations per minute and correction for energy spillover of each isotope. Column calibration was obtained with radioactive D3 and 25(OH)D3 standards added to, and extracted from the liver homogenate of an untreated vitamin Ddepleted rat. The identity ofthe compounds recovered under the D3 and 25(OH)D3 peaks was further confirmed by comigration with pure crystalline standards in the straight-phase HPLC system described above.
Radioactivity associated with peaks more polar than 25(OH)D3 in the silic acid chromatograms was quantitated but not identified. Overall isotope recovery was 70.1±6.2% for 14C and 87.5±3.7% for 3H with variations in recovery being independent of supplementation regimens.
In vitro metabolism of 3H]D3
In a second series of experiments, animals were pretreated as described above but were killed by exsanguination through the abdominal aorta under light ether anesthesia after 7 Determination ofthe hepatic microsomal vitamin D3-25 hydroxylase activity. Cytochrome P450 content was determined on the 105,000-g pellet resuspended in 0.1 M potassium phosphate buffer, pH 7.4, using an isosbestic point of 490 nm (Q = 91 nM * cm-') as described by Omura and Sato (18) . All cytochrome P-450 determinations were made on an Aminco DW-2 dual beam spectrophotometer (American Instruments Co., Silver Spring, MD). All enzyme assays were performed on microsomal suspensions as previously described (19) Fractions of 1 min were collected and counted in 6 ml Biofluor in a liquid scintillation spectrometer.
Statistical analysis
Data are presented as means±SEM unless otherwise specified. The effects of supplementation regimens were analyzed either by a 2 X 4 factorial analysis of variance (initial/final vs. treatments) or by simple analysis of variance according to Winer (20) . Orthogonal contrasts between subgroups were calculated by the method of Dunnett (21) . Comparisons ofthe slopes of 25(OH)_[3HJD3 elimination curves were done as described by Kleinbaum and Kupper (22) .
Results
Systemic effects ofcalcium and 1,25(0H)2D3 supplementation. Fig. 1 Plasma 25(OH)D3 concentrations were not influenced by the supplementation regimens and were found to be undetectable in one-third of the samples while remaining below 0.4 ng * ml-' in all other samples.
Upon initiation of the supplementation regimens, body weights were similar in all treatment groups (230±6 g for unsupplemented controls and 237+5, 239±11, and 241± 10 g for calcium-supplemented, 7 and 65 pmol 1,25(OH)2D3 -24 h-' groups, respectively, NS). However, they increased significantly more following 7 d of exogenous 1,25(OH)2D3 infusion than following that ofvehicle, or 10 d oforal calcium supplementation (275±7 and 271±9 g for. the 7 and 65 pmol 1,25(OH)2D3.24 h-' groups vs. 250±10 and 251 ±+11 g for the unsupplemented controls and calcium-supplemented animals, respectively, P < 0.05). Simi-larly, liver weights were found to be significantly larger (P < 0.05) in the 7 and 65 pmol 1,25(OH)2D3 -24 h-' groups (3.78±0.11 and 3.84±0.08 g-100 g body wt', respectively) than in vehicle-infused or calcium-supplemented rats (3.58±0.12 and 3.51±0.12 g -100 g body wt-', respectively 14C, whether in the kidneys or in other tissues, and remained at levels below 1% of the injected dose in the liver and kidney, and below 0.1% in muscle and adipose tissue. The molar concentrations of sequestered hepatic 14C activity present in the form ofD3, 25(OH)D3, or more polar metabolites are presented in Table II ( Hepatic microsomal Dr25 hydroxylase. The effects of in vivo calcium or hormonal supplementation on the in vitro assay of the hepatic microsomal D3-25 hydroxylase activity are summarized in Table III . Microsomal cytochrome P450 specific content was not significantly affected by the supplementation regimens. On the other hand, an overall significant effect of treatments on the D3-25 hydroxylase activity was observed when the latter was expressed in terms ofthe microsomal protein present in the assay (P < 0.05). This effect was primarily attributed to a significant increase in enzyme activity in calcium-supplemented animals when compared with controls (P < 0.01). 1,25(OH)2D3 infusion also increased D3-25 hydroxylase activity but the increase did not reach statistical significance. When the D3-25 hydroxylase activity was expressed in terms of the cytochrome P450 content (molar activity), a similar pattern ofeffects was obtained, albeit more discrete and thus statistically nonsignificant. however, found in slightly lower concentrations in the liver than in the plasma of animals receiving the high 1,25(OH)2D3 dose as compared with the other groups, suggesting that these metabolites might have been formed in organs or tissues other than the liver.
Recent in vitro studies in the rachitic rat liver (12, 23) as well as in vivo experiments in man (13) have brought forward the observation of decreased 25(OH)D3 concentrations when the substrate, vitamin D3, and its hormonal metabolite, 1,25(OH)2D3, were introduced concomitantly. Both groups interpreted their data as indicative of an inhibitory effect of 1,25(OH)2D3 on the hepatic D3-25-hydroxylase, and a scheme ofregulation ofhepatic vitamin D metabolism has been proposed on that basis (24) . In the in vitro studies mentioned above (12, 23) , however, D3 together with supraphysiological or pharmacological doses of 1,25(OH)2D3 were introduced directly in vitro instead of conditioning the enzymatic processes involved in the production of 25(OH)D3 by an in vivo pretreatment with the hormone as was done during the present studies. Studies on the vitamin D3-25-hydroxylase in the presence of high doses of 1,25(OH)2D3 in the incubation media, or in a closed recirculating isolated perfused liver system, as was done by Baran and Milne (12, 23) 
